News - Licensing, Boehringer Ingelheim

Filter

Popular Filters

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord

10-01-2014

US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19-06-2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project

23-01-2013

Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko

15-01-2013

UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin

08-01-2013

US drug major Eli Lilly (NYSE: LLY) and German independent drugmaker Boehringer Ingelheim said yesterday…

Boehringer IngelheimDiabetesEli LillyempagliflozinLicensingLY2605541PharmaceuticalResearch

Ensemble Thera in deal worth a potential $186 million with Boehringer Ingelheim

05-11-2012

USA-based drug discovery firm Ensemble Therapeutics says it has initiated a research collaboration with…

Boehringer IngelheimEnsemble TherapeuticsLicensingPharmaceuticalResearch

XOMA and Servier sign manufacturing deal with Boehringer for gevokizumab

06-08-2012

US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) its partner France's Laboratoires Servier…

Boehringer IngelheimgevokizumabLicensingOphthalmicsPharmaceuticalProductionServierXOMA Corp

Boehringer Ingelheim acquires Funxional products

24-07-2012

German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global…

Anti-Arthritics/RheumaticsBoehringer IngelheimFunxional TherapeuticsFX125LLicensingPharmaceuticalRespiratory and Pulmonarysomatotaxin

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Boehringer Ingelheim links with Xencor on MAb supply

23-02-2012

Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead

07-10-2011

Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

Back to top